Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Exo-hydrogel therapy: a revolutionary approach to managing diabetic complications

Meng Y., Sun J., Ma Y., Kong C.

Narrative Review on Chronic Wound, published in J Nanobiotechnology (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Nanobiotechnology (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40790200
PMCID
PMC12337418
DOI
10.1186/s12951-025-03621-6
Citations
7

Abstract (original English)

This review systematically examines the transformative potential of Exosome-hydrogel (Exo-gel) composite systems in combating diabetic complications, with a particular emphasis on their macromolecular interactions and therapeutic implications. By synergistically integrating the bioactive cargo of Exos with the structural tunability of polysaccharide-based hydrogels, this advanced biomaterial platform addresses critical limitations in conventional therapies through the spatiotemporally controlled delivery of regenerative factors. We highlight how the dynamic interplay between natural biopolymers and exosomal surface proteins enhances extracellular matrix (ECM) remodeling while maintaining bioactive stability, a crucial advancement for chronic diabetic conditions. A comprehensive analysis reveals that Exo-gel systems demonstrate therapeutic efficacy in three key pathological contexts: (1) neural regeneration via Schwann cell modulation, (2) angiogenesis restoration through VEGF/VEGFR signaling pathways, and (3) chronic wound healing mediated by macrophage polarization. Our critical appraisal of preclinical evidence positions Exo-gel technology as a paradigm-shifting approach in diabetes care, offering solutions to current challenges in sustained drug delivery and targeted tissue regeneration, while outlining future translational pathways for bioengineered therapeutic systems.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Extracellular MatrixAnimalsHumansDiabetes ComplicationsBiocompatible MaterialsHydrogelsDrug Delivery SystemsNerve RegenerationWound HealingSignal Transduction

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research